Surrozen Inc (SRZN)

Surrozen Inc. is a biotechnology company focused on discovering and developing drug candidates that selectively modulate the Wnt pathway to support tissue repair. The company’s pipeline centers on antibody-based therapeutics designed for a range of disease areas, including conditions affecting the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its lead programs include SZN-814, which combines Fzd4 agonism and VEGF antagonism for diabetic macular edema, wet age-related macular degeneration, and retinopathy indications; SZN-8143, which adds interleukin-6 targeting for diabetic macular edema, wet AMD, and uveitic macular edema; SZN-113 for Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4-targeted bispecific antibody for retinal vascular diseases. Surrozen also maintains collaboration and license arrangements with Boehringer Ingelheim and a research collaboration with TCGFB, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.